5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.35▲ | 2.35▲ | 2.35▲ | 2.33▲ | 2.23▲ |
MA10 | 2.34▲ | 2.33▲ | 2.34▲ | 2.25▲ | 2.47▼ |
MA20 | 2.34▲ | 2.32▲ | 2.32▲ | 2.20▲ | 2.68▼ |
MA50 | 2.31▲ | 2.30▲ | 2.25▲ | 2.48▼ | 3.03▼ |
MA100 | 2.27▲ | 2.19▲ | 2.18▲ | 2.64▼ | 3.59▼ |
MA200 | 2.17▲ | 2.18▲ | 2.34▲ | 2.90▼ | 17.89▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.002▲ | 0.002▲ | 0.001▲ | 0.045▲ | -0.032▼ |
RSI | 56.137▲ | 57.029▲ | 59.240▲ | 52.160▲ | 40.833▼ |
STOCH | 89.286▲ | 75.000 | 77.222 | 87.455▲ | 27.148 |
WILL %R | -10.000▲ | -10.000▲ | -8.333▲ | -4.819▲ | -61.667 |
CCI | 78.961 | 79.020 | 77.690 | 105.668▲ | -68.971 |
CDL | $VTGN Doji Candlestick Pattern Detected | Set Alert |
Friday, April 25, 2025 11:16 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company ...
|
Thursday, April 17, 2025 05:29 AM
The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose ...
|
Thursday, April 17, 2025 01:30 AM
SOUTH SAN FRANCISCO, Calif., April 17, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
02/05/25 | 2.36 | 2.36 | 2.36 | 2.36 | 21,796 |
01/05/25 | 2.33 | 2.38 | 2.26 | 2.36 | 60,528 |
30/04/25 | 2.27 | 2.362 | 2.20 | 2.34 | 112,459 |
29/04/25 | 2.27 | 2.32 | 2.27 | 2.29 | 41,342 |
28/04/25 | 2.24 | 2.33 | 2.23 | 2.29 | 68,092 |
25/04/25 | 2.31 | 2.34 | 2.215 | 2.22 | 72,931 |
24/04/25 | 2.18 | 2.34 | 2.17 | 2.34 | 134,700 |
23/04/25 | 2.09 | 2.19 | 2.08 | 2.18 | 112,480 |
22/04/25 | 2.12 | 2.1201 | 2.00 | 2.05 | 166,044 |
21/04/25 | 2.115 | 2.14 | 2.02 | 2.10 | 103,206 |
|
|
||||
|
|
||||
|
|